Approach to chest pain and acute myocardial infarction

S Pandie,1 FCP (SA), Cert Cardiology (SA); D Hellenberg,2 MFamMed, FCFP (SA); F Hellig,3 BSc, MB BCh, FCP (SA), FSCAI; M Ntseke,1 MD, PhD

1 Division of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2 Division of Family Medicine, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
3 Sunninghill and Sunward Park Hospitals, Johannesburg, South Africa

Corresponding author: S Pandie (s.pandie@uct.ac.za)

Patient history, physical examination, 12-lead electrocardiogram (ECG) and cardiac biomarkers are key components of an effective chest pain assessment. The first priority is excluding serious chest pain syndromes, namely acute coronary syndromes (ACSs), aortic dissection, pulmonary embolism, cardiac tamponade and tension pneumothorax. On history, the mnemonic SOCRATES (Site Onset Character Radiation Association Time Exacerbating/releasing factor and Severity) helps differentiate cardiac from non-cardiac pain. On examination, evaluation of vital signs, evidence of murmurs, rubs, heart failure, tension pneumothoraces and chest infections is important. A 12-lead ECG should be interpreted within 10 minutes of first medical contact, specifically to identify ST elevation myocardial infarction (STEMI). High-sensitivity troponins improve the rapid rule-out of myocardial infarction (MI) and confirmation of non-ST elevation MI (NSTEMI). ACS (STEMI and NSTEMI/unstable angina pectoris (UAP)) result from acute destabilisation of coronary atheroma with resultant complete (STEMI) or subtotal (NSTEMI/UAP) thrombotic coronary occlusion. The management of STEMI patients includes providing urgent reperfusion: primary percutaneous coronary intervention (PCI) if available, deliverable within 60 - 120 minutes, and fibrinolysis if PCI is not available. Essential adjunctive therapies include antiplatelet therapy (aspirin, P2Y₁₂ inhibitors), anticoagulation (heparin or low-molecular-weight heparin) and cardiac monitoring.

History

The history is the most useful component when evaluating chest pain, as both normal and abnormal investigations (such as the ECG, cardiac biomarkers and chest radiograph (CXR)) must be interpreted in the context of the patient’s history.

The mnemonic SOCRATES (Site Onset Character Radiation Association Time Exacerbating/releasing factor and Severity) helps differentiate cardiac v. non-cardiac (respiratory, gastric or musculoskeletal) pain. Features that make a diagnosis of ACS likely include: central (retrosternal) location; sudden or acute onset; heavy or burning sensation with radiation to the arm or jaw; associated dyspnoea, nausea or sweating; duration >15 minutes; relief of symptoms by nitrates; worsening of symptoms by activity; chest or left-arm discomfort that is the same in nature as previously documented angina; and a known history of CAD (including prior MI). Atypical presentations need to be considered in the elderly, diabetics and women.

At the primary care level, the Marburg Heart Score has been shown to have excellent negative predictive value (Table 2). Based only on variables acquired on history and examination, it is an easy-to-apply clinical prediction rule.

Physical examination

All patients presenting with acute chest pain should undergo a thorough physical examination. In ACS, the cardiac examination is often unremarkable, but specific attention should be paid to the vital signs (pulse and BP), features of heart failure, and auscultation precordial murmurs and rubs. The presence of transient mitral regurgitation, hypotension, diaphoresis, pulmonary oedema, crackles or signs of extracardiac vascular disease is highly suggestive of ACS. ACS is less likely if the presenting chest pain is reproducible by chest palpation. Examination of the respiratory system should exclude...
tension pneumothoraces and chest infections, while abdominal examination may reveal abdominal aetiologies.

12-lead ECG

Patients presenting with acute chest pain should have a 12-lead ECG performed and interpreted within 10 minutes of first medical contact. If the initial ECG is non-diagnostic but the diagnosis of ACS is highly suspected, serial ECGs should be performed (at 3 hours, 6 hours, 9 hours and 24 hours, or on recurrence of symptoms), including ECGs with additional leads for evaluation of the posterior-lateral myocardial wall V7-V8-V9 or V3R-V4R-V5R. ACS diagnostic features on the ECG include ST elevation, ST depression, T-wave inversion, and positive biomarkers may reflect myocardial injury secondary to non-cardiac diagnosis: Gastrointestinal pathology – gastroscopy; GI pathology – gastroscopy; Myocarditis – echocardiogram for wall motion abnormalities; Aortic dissection – CT angiogram, echocardiogram; Pericardial effusion – echocardiogram or ultrasound; and repeat if ongoing chest pain or recurrent chest pain, or at 3 hours).

Cardiac biomarkers

Cardiac biomarkers reflect myocardial cell injury, the hallmark of MI. Pathophysiologically, MI results from ischaemia sufficient to cause cell death, with the release of cellular proteins and enzymes. Cardiac troponins I and T have been shown to be the most sensitive indicators of cardiac injury, as well as being predictors for short- and long-term outcomes as regards death and MI.\[^1^]\ The introduction of high-sensitivity troponin (hs-Tc) assays have improved rapid rule-out MI, and the confirmation of non-ST elevation MI (NSTEMI).\[^2^]\ It is important to understand that the increased sensitivity of the test results in lower specificity. To this end, the universal classification of MI was revised in 2012, acknowledging that for practical purposes, the diagnosis of ST elevation MI (STEMI) is made in the correct clinical setting with the appropriate ECG changes, and that MI without ST elevation (NSTEMI) requires positive biomarkers (Table 3). If serial biomarkers are negative, this implies no MI has occurred, but the patient may still require treatment for unstable angina. In addition, positive biomarkers may reflect myocardial injury secondary to non-coronary causes – usually as a result of imbalance between myocardial oxygen supply and demand – and should therefore be interpreted in the clinical context of the presentation.\[^3^]\

CXR

The CXR is helpful when pneumothorax or pneumonia, aortic dissection (wide mediastinum) or pulmonary embolism (oligemia of lung fields or wedge-shaped infarcts) is suspected. If, on the
basis of the ECG, ACS is suspected, the urgency of obtaining a CXR should be relegated and implementation of management plans prioritised.

The management of ACSs

The clinical presentations of CAD include stable angina pectoris, silent ischaemia, unstable angina, MI, heart failure and sudden death.[6] ACSs result from acute destabilisation of coronary atheroma with resultant complete or subtotal thrombotic coronary occlusion. Ischaemic discomfort or chest pain is experienced because of reduction in blood flow to the myocardium.

**STEMI**

**Pathophysiology and initial diagnosis**

Plaque disruption exposes thrombogenic substances, resulting in intracoronary thrombus formation. Local anticoagulant production is increased and, if successful, will result in thrombus resolution and arrest of the infarction. However, if complete arterial occlusion occurs, myocardial ischaemia followed by infarction results, producing the typical ST elevation seen on the 12-lead ECG. Diagnostic patterns of ST elevation vary depending on which epicardial vessel is involved (Fig. 2).

**Immediate management**

The optimal management of STEMI patients includes providing the fastest, safest, most effective method of reperfusion therapy available, i.e. primary percutaneous coronary intervention (PPCI) or fibrinolysis, while simultaneously initiating essential adjunct therapies and monitoring (Fig. 3). Unless contraindicated, all patients should receive antiplatelet therapy (aspirin with P2Y12 inhibitors such as ticagrelor, prasugrel or clopidogrel) and anticoagulation (unfractionated or low-molecular-weight heparins (LMWHs) dosed to body weight). Patients should be connected to a cardiac monitor capable of cardioversion and transcutaneous pacing. Oxygen should be administered if the patient is hypoxic, and opioids for pain relief, breathlessness and anxiety are essential.[9]

**Prehospital logistics of care**

The lack of a formal STEMI referral network for both public and private sectors makes decisions regarding reperfusion therapy challenging, and often impedes the rapid administration of reperfusion therapy.[10] Important timeframes that govern timely STEMI care are outlined in Fig. 4. Prehospital logistics and patient-practitioner education should aim to reduce delays from time of symptom onset to definitive reperfusion.[9,11]

**Reperfusion therapy**

This includes PPCI, fibrinolysis and pharmaco-invasive strategies. Selecting the most appropriate reperfusion strategy depends on three key factors: the time delay from symptom onset to first medical contact; availability; and clinical factors that may favour one strategy over the other.

**Patients presenting within 12 hours of onset of symptoms (or since worse exacerbation)**

As a general guide, STEMI patients presenting to PCI-capable facilities should be offered PPCI (preferably within 60 minutes). If there is an anticipated delay of >120 minutes from the time of first medical contact, fibrinolysis should be administered. Patients presenting to
non-PCI-capable facilities should be considered for fibrinolysis, or transfer for PCI if PCI can be ensured within 120 minutes. It is important to remember that PPCLI and fibrinolysis are of equivalent efficacy for patients presenting within 3 hours of symptoms, and every effort should be made not to delay reperfusion.\(^\text{[13]}\)

**Fibrinolysis and pharmaco-invasive strategies**

In most sub-Saharan countries, access to PCI-capable facilities is limited. Fibrinolysis is therefore the first choice reperfusion therapy. Clear contraindications to fibrinolysis need to be identified during the initial assessment (Table 4). alteplase (tPA) with concomitant heparin was shown to be more effective than streptokinase (one fewer death per 100 patients treated, at the expense of three additional strokes). Tenectaplaste is equivalent to accelerated tPA for 30-day mortality (with lower rate of bleeding).\(^\text{[13,14]}\) Non-patient-related factors when considering choice of fibrinolysis include cost, ease of administration and administration in hospital or before being admitted.

Pharmacoinvasive management refers to the combination of fibrinolysis and angiography, with a view to PCI of the culprit lesion. Patients who have had successful fibrinolysis can be referred to a PCI-capable centre for routine angiography and PCI within 24 hours of completing fibrinolysis. This strategy has been shown to reduce recurrent MI and urgent revascularisation for recurrent ACSs, and is currently a very attractive option in South African (SA) clinical settings.\(^\text{[15]}\)

**Patients presenting after 12 hours of symptom onset (or since worse exacerbation)**

Beyond 12 hours, fibrinolysis is far less effective than PCI, while still carrying the risk of bleeding. Decisions regarding reperfusion should therefore be based on an individual basis. Patients with persistent myocardial ischaemia, hypotension, haemodynamic instability or ventricular arrhythmias should be considered for referral for angiography and PCI. Stable patients should receive antiplatelet therapy and anticoagulation with unfractionated heparins or LMWHs.\(^\text{[12]}\)

**Failed fibrinolysis**

The 12-lead ECG should be repeated 60 (tPA) - 90 (streptokinase) minutes after fibrinolysis to assess therapeutic success. Failed fibrinolysis is indicated by failure of the ST elevation to reduce by >50% with or without persistent myocardial ischaemia. These patients do not benefit from repeat fibrinolysis, and should be considered for urgent rescue PCI, ideally within 12 hours.\(^\text{[12]}\)

**Table 3. Universal classification of MI (adapted from Thygesen et al.\(^\text{[7]}\))**

| Type | Description |
|------|-------------|
| Type 1: Spontaneous MI | Related to atherosclerotic plaque rupture, ulceration, erosion or dissection with resultant coronary luminal thrombus in one or more coronaries, leading to decreased myocardial blood flow with ensuing myocyte necrosis. Patients may have underlying CAD (severe obstructive or mild non-obstructive) or no CAD. |
| Type 2: MI secondary to an ischaemic imbalance | Myocardial injury with necrosis secondary to an imbalance between myocardial oxygen supply and demand. Patients may or may not have underlying CAD. Common examples include coronary endothelial dysfunction, coronary artery spasm, tachycardias, bradycardias, anaemia, respiratory failure, hypotension and hypertension (with or without left ventricular hypertrophy). |
| Type 3: MI resulting in death when biomarker values are unavailable, or at autopsy | Cardiac death with symptoms and ECG changes of myocardial ischaemia or infarction, but death occurred before confirmatory biomarkers were obtained. |
| Types 4a and 4b: MI related to PCI | PCI-related infarction with elevation in cardiac troponins, symptoms of myocardial ischaemia, new ECG changes, angiographic changes (loss of vessel patency or new wall motion abnormality), or stent thrombosis. |
| Type 5: MI related to CABG | CABG-related infarction with elevation in cardiac troponins, symptoms of myocardial ischaemia, new ECG changes, angiographic changes (new graft or native coronary occlusion or new wall motion abnormality). |

PCI = percutaneous coronary interventions; CABG = coronary artery bypass grafting.

**NSTEMI and unstable angina**

**Pathophysiology and initial diagnosis**

The pathophysiology of most NSTEMIs involves the rupture of a vulnerable atheromatous plaque with subsequent thrombus formation, leading to reduced blood flow and ischaemia, with or without MI (NSTEMI or unstable angina (UA), respectively).

The diagnosis is confirmed by the presence of prolonged (>20 minutes) ischaemic chest pain, new-onset Canadian Class II or III angina, acute deterioration of stable chronic angina or angina following a recent MI, and the absence of ST elevation on the 12-lead ECG. Atypical complaints (including silent ischaemia, epigastric pain, indigestion and dyspnoea) can occur in older patients (>75 years), women and patients with diabetes, chronic kidney disease or dementia. In these settings, ST-T wave abnormalities on ECG should prompt rapid rule-out or rule-in of ACS using hs-Tc assays (Fig. 5).

**Immediate management and risk stratification**

The immediate care of UA and NSTEMI patients involves two key steps: (i) risk stratification using validated ischaemia and bleeding prediction tools before deciding on pharmacological and invasive management strategies; and (ii) the administration of evidence-based therapies. If there are no contraindications, a patient with a suspected diagnosis of ACS should receive antiplatelet therapy (aspirin and clopidogrel), anticoagulation therapy (unfractionated heparins or LMWHs, or indirect factor Xa inhibitors (fonpaturaxan)), and anti-ischaemic agents (β-blockers, or calcium channel blockers and nitrates).

Validated ischaemic risk prediction scores (Thrombolysis in MI (TIMI) Risk Score and the Global Registry of Acute Coronary Events (GRACE) Risk Score) use demographic, clinical, ECG and biochemical variables to estimate the short-, intermediate- and long-term prognosis related to the current presentation (Table 5). The validated CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of ACC/AHA guidelines) bleeding score combines eight predictors of major bleeding, allowing a physician to estimate the baseline risk of in-hospital major bleeding, therefore complementing ischaemic risk prediction tools. These scores are readily available as applications on smartphones and tablets, making them easy to use in daily practice. Patients with intermediate- to high-risk scores should be considered for invasive management, and advanced for coronary angiography with a view to revascularisation. Independent of risk
scores, patients with significant rise or fall of troponin levels, dynamic ECG changes and ongoing ischaemia should be considered for invasive management.

**Timing of angiography and intervention**

High-risk patients benefit from revascularisation therapy. Patients with ongoing ischaemia, acute heart failure, life-threatening ventricular arrhythmias or haemodynamic instability should be considered for immediate intervention regardless of biomarkers and ECG changes. Patients with high-risk scores who have clinically stabilised should be considered for angiography within 48 hours of admission. Low-risk patients may be managed medically, or have coronary angiography deferred. These timelines are a guide and may differ based on the availability of PCI-capable centres.

**Hospitalisation and discharge**

All ACS patients should be managed in a high-care setting, specifically for the rapid identification and management of haemodynamic (cardiogenic shock) and arrhythmic (ventricular tachycardia and fibrillation) complications, as well as bleeding (access site or secondary to fibrinolysis) and recurrent infarction. ECG monitoring and bed rest should continue for at least 24 hours after successful reperfusion and symptom resolution.

Chronic medications that offer mortality benefit should be introduced while in hospital (unless contraindicated). Dual antiplatelet therapy should be continued for 1 year, unless there are specific reasons to stop sooner. The introduction of β-blockers, renin-angiotensin system inhibitors, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) or aldosterone antagonists should be specific to the individual, rather than introduced as a routine ‘cocktail’. The early introduction of high-dose HMG-CoA reductase inhibitors (statins) is also associated with improved survival and reduced morbidity. Beta-blockers should be provided to all patients within 24 hours unless there is evidence of haemodynamic compromise, congestive heart failure or brady-arrhythmias (such as heart block). Patients with anterior MI, evidence of heart failure or depressed left ventricular systolic function should receive ACE-Is or ARBs, plus an aldosterone antagonist. Lifestyle and risk factor modification including smoking cessation, diet, physical activity and BP control is essential. Patients who require surgical revascularisation should be discussed with a combined heart team (interventional cardiologist, clinical cardiologist and cardiothoracic surgeon) regarding the optimal timing of surgery (in-patient v. elective re-admission).

---

**Fig. 2. ST elevation MI variations.**

| ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV in all leads other than leads V2-V3 where the following cut-points apply: ≥0.2 mV in men ≥40 years; ≥0.25 mV in men <40 years; ≥0.15 mV in women |
|---|
| Anterior STEMI: Typical ST elevation V2-V5. 2A |
| Inferior STEMI: ST elevation in II, III, aVF. Also note the heart block. 2B |
| Lateral STEMI: ST elevation I and aVL, also V5 and V6. ST depression noted II, III, aVF, V1, V2, V3. 2C |
| Posterior STEMI: Deep ST depression V1-V3 with prominent R waves V2, V3. When the ECG is viewed ‘from behind’, ST elevation in V1, V2, V3 is clearly seen. 2D and E |
| Left bundle branch block (new or presumed new) in the setting of ACS. Eponymous signs like Cabrera’s (notching in S-wave of V3 or V4) and Chapman’s (notching in R-wave of I, aVL, or V6) have poor sensitivity, but reasonable specificity. Using the Sgarbossa criteria may be helpful. 2F |
| De Winter’s sign (proximal LAD occlusion): 1 - 3 mm upsloping ST segment depression at the J-point in leads V1-V6 that continue into tall, positive symmetrical T-waves. QRS complexes are not wide (<120 ms), and there may be loss of precordial R-wave progression. May have ST elevation (1 - 2 mm) in aVR. 2G |
| Atypical ECG presentations that deserve prompt management in patients with signs and symptoms of ongoing myocardial ischaemia include left bundle branch block, ventricular paced rhythms, isolated posterior MI, and ST elevation in lead aVR. |
Less common ACS aetiologies

Infrequently, aetiologies other than ruptured atheroma result in ACS. Examples include coronary artery embolism (in patients with atrial fibrillation, cardiomyopathy with ventricular clot or septic emboli from infective endocarditis), spontaneous coronary dissection (in patients with fibromuscular dysplasia, coronary vasculitis or thyrotoxicosis), coronary artery spasm (recreational drug use, de novo) and stress-induced cardiomyopathy (Takotsubo non-ischaemic cardiomyopathy). Careful history and clinical examination can often identify these patients prior to definitive ACS care. Even so, the general principles of management are as outlined above.

ACFs in sub-Saharan Africa

ACFs are becoming increasingly prevalent in sub-Saharan Africa, with patients displaying similar myocardial risk factors to those of the developed world.[16,17] There are limited data regarding ACFs in the SA context, with observational data suggesting that there are high intervention rates and frequent use of evidence-based pharmacological therapies with comparative outcomes when compared with international standards.[18] These data reflect mainly the care delivered in the private sector, and do not fully represent care from the public sector where resources are limited and timely presentation to healthcare facilities capable of managing ACFs is often delayed.[19,20] Our current challenge is the provision of equal access and quality ACS care to all sectors of the SA population. This would entail reliance on the pharmaco-invasive strategy (routine and rescue) until there is adequate infrastructure expansion to accommodate the roll-out of a comprehensive, organised, hub-and-spoke PPCI service. Initiatives such as the European Society of Cardiology ‘Stent-for-Life’ project and planned national ACS registries could be the stepping stones to formalising management of ACFs on a national level.

Table 4. Contraindication to fibrinolysis

| Absolute                                                                 | Relative                                                                 |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Previous intracranial haemorrhage or stroke of unknown origin at any time | Transient ischaemic attack in the preceding 6 months                      |
| Ischaemic stroke in the preceding 6 months                                | Oral anticoagulation therapy                                              |
| Central nervous system damage or neoplasm or atrioventricular malformations | Pregnancy or within 1 week post partum                                   |
| Recent major trauma/surgery/ head injury (within preceding 3 weeks)      | Refractory hypertension (systolic BP >180 mmHg and/or diastolic BP >110 mmHg) |
| Gastrointestinal bleeding within the past month                           | Advanced liver disease                                                   |
| Known bleeding disorder (excluding menses)                               | Infective endocarditis                                                   |
| Aortic dissection                                                        | Acute peptic ulcer                                                      |
| Non-compressible puncture in the past 24 hours (e.g. liver biopsy, lumbar puncture) | Prolonged or traumatic resuscitation                                    |

References

1. Bössner S, Becker A, Hausenbriiter J, et al. Chest pain in primary care: Epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009;15(3):141-146. [http://dx.doi.org/10.1186/14787526]
2. Kramer S, Rabenstrief N, Hausenbriet J, Bössner S, Braun E, Donner-Banzhoff N. Do guidelines on first impression make sense? Implementation of a chest pain guideline in primary care: A systematic evaluation of acceptability and feasibility. BMC Family Practice 2011;12:128. [http://dx.doi.org/10.1186/1472-6921-12-128]
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Executive summary. Circulation 2007;116(7):e30-87. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.169702]
4. Hausenbriiter J, Bössner S, Vauth P, et al. Ruling out coronary heart disease in primary care: External validation of a clinical prediction rule. Br J Gen Pract 2012;62(599):415-421. [http://dx.doi.org/10.3399/bjgp12X649106]
5. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335(18):1342-1349. [http://dx.doi.org/10.1056/NEJM199610153351802]
6. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361(9):858–867. [http://dx.doi.org/10.1056/NEJMoa0900428]

7. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60(16):1581–1598. [http://dx.doi.org/10.1016/j.jacc.2012.08.001]

8. Hamm CW, Bassand J­P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST­segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST­segment elevation. Eur Heart J 2011;32(23):2999–3054. [http://dx.doi.org/10.1093/eurheartj/ehr236]

9. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST­segment elevation. Eur Heart J 2012;33(20):2569–2619. [http://dx.doi.org/10.1093/eurheartj/ehs215]

10. Maharaj RC, Geduld H, Wallis LA. Door­to­needle time for administration of fibrinolytics in acute myocardial infarction in Cape Town. S Afr Med J 2012;102(4):241–244.

11. Delport R. Towards developing guidelines and systems of care to facilitate early reperfusion for ST­elevation myocardial infarction in Africa. Cardiovasc J Afr 2012;23(7):365–370. [http://dx.doi.org/10.5830/CVJA­2012­017]

12. Harker M, Carville S, Henderson R, Gray H. Key recommendations and evidence from the ACCES (Access to Care: Early Reperfusion of Acute Myocardial Infarction) registry: Cardiovascular topics. Cardiovasc J Afr 2012;23(6):628–633. [http://dx.doi.org/10.1111/j.11169-1444.2012.00948.x]

13. Lubitz J, Riley G. Trends in inpatient payments in the last year of life. N Engl J Med 1993;328(15):1092­1096. [http://dx.doi.org/10.1056/NEJM199301313281506]

14. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT­2) Investigators, van de Werf F, Adgey J, et al. Single bolus tenecteplase compared with front­loaded alteplase in acute myocardial infarction: The ASSENT­2 double­blind randomised trial. Lancet 1999;354(9180):716–722.

15. Welsh RC, van de Werf F, Westerhout CM, et al. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the Strategic Reperfusion Early After Myocardial Infarction [STREAM] Study). Am J Cardiol 2014;114(6):811–819. [http://dx.doi.org/10.1016/j.amjcard.2014.06.011]

16. Shavadia J, Y onga G, Otieno H. A prospective review of acute coronary syndromes in an urban hospital in sub­Saharan Africa. Cardiovasc J Afr 2012;23(6):318–321. [http://dx.doi.org/10.5830/CVJA­2012­002]

17. Ntsekhe M, Damasceno A. Recent advances in the epidemiology, outcome, and prevention of myocardial infarction and stroke in sub­Saharan Africa. Heart 2013;99(17):1230–1235. [http://dx.doi.org/10.1136/heartjnl­2012­303585]

18. Schamroth C. Management of acute coronary syndrome in South Africa: Insights from the ACCESS (Access to Care: Early Reperfusion of Acute Myocardial Infarction) registry: Cardiovascular topics. Cardiovasc J Afr 2012;23(7):365–370. [http://dx.doi.org/10.1111/j.11169-1444.2012.00948.x]

19. De Winter RJ, Verschuren NFV, Willems HJ, Wilke AM. A new ECG sign of proximal LAD occlusion. N Engl J Med 2008;359(19):2071–2073. [http://dx.doi.org/10.1056/NEJMoa0804737]

Table 5. TIMI, GRACE and CRUSADE risk scores

| TIMI risk score for UA/NSTEMI | Risk of cardiac events (%) by 14 days |
|------------------------------|--------------------------------------|
| Variable                      | Points | Risk score | Death or MI | Death, MI or urgent revascularisation |
| Age ≥65 years                 | 1      | 0 – 1      | 3           | 5                                       |
| ≥3 CAD risk factors (family history, raised cholesterol, diabetes, hypertension) | 1 | 2 | 3 | 8 |
| Known CAD (stenosis ≥50%)     | 1      | 3          | 5           | 13                                      |
| Aspirin use in past 7 days    | 1      | 4          | 7           | 20                                      |
| Recent severe angina (last 24 hours) | 1 | 5 | 12 | 26 |
| Elevated cardiac biomarkers   | 1      | 6 – 7      | 19          | 41                                      |
| ST deviation ≥0.5 mm          | 1      | 8          |             |                                         |

| GRACE score for UA/NSTEMI | |
|---------------------------|--|
| Variables*                | |
| Age                        | |
| Heart failure              | |
| Peripheral vascular disease| |
| Admission systolic BP      | |
| Killip class               | |
| Elevated cardiac biomarkers| |
| Initial serum creatinine   | |
| Cardiac arrest on admission| |
| ST segment deviation       | |

6 months post-discharge mortality

| CRUSADE bleeding risk score | In-hospital mortality |
|-----------------------------|-----------------------|
| Variables†                  | Risk categories | GRACE score | Death, % |
| Age                         | Low               | 1 – 108     | <1       |
| Heart failure               | Intermediate      | 109 – 140   | 1 – 3    |
| Peripheral vascular disease | High              | 141 – 372   | >3       |
| Admission systolic BP       | Low               | 1 – 88      | <3       |
| Killip class                | Intermediate      | 89 – 118    | 3 – 8    |
| Elevated cardiac biomarkers | High              | 119 – 263   | >8       |

| Variables†                  | Risk categories | CRUSADE score | Bleeding risk, % |
| Baseline haematocrit        | Very low         | 1 – 20        | 3                |
| Estimated glomerular filtration rate | Low          | 21 – 30        | 5.5              |
| Heart rate on admission     | Moderate         | 31 – 40       | 8.6              |
| Systolic BP on admission    | High             | 41 – 50       | 12               |
| Prior vascular disease      | Very high        | 51 – 90       | 20               |

| Diabetes mellitus           | Signs of congestive heart failure on admission | |
| Gender                      |                                                     | |

*Variables are inserted into an online calculator to generate the GRACE score (www.gracescore.org).

†Variables are inserted into an online calculator to generate the CRUSADE score (www.crusadebleedingscore.org).